Compare Harley-Davidson Inc (HOG) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Harley-Davidson (HOG) trades at $26.95, up 0.04% on the day, with a bullish technical signal and mixed earnings history. The company reported Q2 2026 EPS of $0.75, beating expectations, but revenue has declined from $5.8B in 2022 to $4.5B in 2025. Valuation ratios appear attractive with a P/E of 14.86 and P/B of 0.9, while analyst consensus is a hold with a $28.50 price target. Recent news includes a data breach investigation and a new product collaboration.

The outlook for HOG is cautious due to declining revenue and profit margins, offset by reasonable valuations and positive technical momentum. Key risks include tariff exposure, competitive pressures, and ongoing data security issues. Upside potential exists if the 'Back to the Bricks' strategy reverses sales trends, but investors should weigh fundamental weaknesses against technical strength.

Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.

The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.